Please assess the completion status of the following clinical trial:

Trial Title: Multi-Modality Therapy for Untreated Patients With Resectable or Marginally Resectable Pancreatic Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven Exocrine Adenocarcinoma of the pancreas~* Clinically resectable or marginally resectable disease~* No prior radiation or chemotherapy for carcinoma of the pancreas~* ECOG performance status of 0-1~* Patients must be medically able to undergo surgical resection~* Patients of child bearing potential must follow study specific precautions~* Women that are lactating will not be excluded on the condition that they dispose their breast milk.~* Adequate hematologic and biochemical parameters.~Exclusion Criteria:~* Prior treatment for pancreatic cancer.~* Concurrent investigational treatments.~* Unresectable pancreatic mass.~* Neuroendocrine Histological pancreatic cancer~* Distant Metastatic disease~* Any condition that, in the option of the investigator, would compromise the well being of the patient or anything that would prevent the patient from meeting or performing study requirements

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Resectable Patients (Type: EXPERIMENTAL): Surgery with Intraoperative Radiation Therapy (IORT). Radiation Therapy within 6-8 weeks after surgery followed by FOLFIRINOX every 2 weeks starting within 12 weeks of surgery
- Marginally Resectable Patients (Type: EXPERIMENTAL): 2-3 cycles of neoadjuvant FOLFIRINOX then restaged, then undergo surgery with Intraoperative Radiation Therapy (IORT) within 2-4 weeks following chemotherapy. Then Radiation Therapy within 6-8 weeks followed by FOLFIRINOX every 2 weeks starting within 12 weeks of surgery for a total of 2-4 cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).